# 04_QA_REPORT.md
# QA Report — PP-0225 Peritoneal Carcinoma as Only Disease

## Identity

| Field | Value |
|---|---|
| PP ID | PP-0225 |
| Title | Peritoneal Carcinoma as Only Disease |
| QA Version | 1.0.0 |
| Production Version | 1.0.0 |
| Status | GOLD |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

## QA Scope

This QA verifies PP-0225 against:

- Approved + Locked Decision Batch;
- CORE_WORKING_RULES v1.7;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1;
- approved Gold Discussion reference;
- supplied gastric-cancer clinical Source Materials;
- PP Registry;
- adjacent PP ownership;
- absolute Gold-depth requirements.

## Layer 1 — Content QA

### Atomic Question

**PASS**

The package answers one specialized clinical question:

> What is special about gastric cancer whose metastatic disease is confined to the peritoneal compartment, and how does the specialized pathway work?

### Scope Completeness

**PASS**

The package covers:

- peritoneal-only definition;
- positive cytology;
- extraperitoneal-disease distinction;
- baseline workup;
- systemic therapy;
- minimum 3-month framework;
- restaging;
- response;
- PCI;
- progression;
- complete cytoreduction;
- incomplete cytoreduction;
- multidisciplinary consultation;
- selected surgery/IC-HIPEC;
- clinical trials;
- best supportive care pathway;
- patient-facing interpretation.

### Scope Restraint

**PASS**

The package does not absorb:

- general peritoneal-carcinomatosis education;
- detailed RECIST;
- detailed imaging;
- detailed systemic regimens;
- detailed surgery;
- dedicated HIPEC evidence/technique;
- palliative/supportive protocols.

## Layer 2 — Clinical QA

### Disease-State Definition

**PASS**

The package defines the pathway as metastatic disease confined to the peritoneal compartment and explicitly distinguishes it from peritoneal plus extraperitoneal disease.

### Positive Cytology

**PASS**

Positive cytology is explicitly included because NCCN includes it in the dedicated pathway. fileciteturn33file14

### Baseline Workup

**PASS**

The package preserves H&P, CT, selected laparoscopy, pathology review and selected additional evaluation.

### Systemic-Treatment Sequence

**PASS**

Systemic therapy is presented as the initial treatment backbone.

### Minimum 3-Month Framework

**PASS**

The package preserves the current NCCN v2.2026 minimum 3-month systemic-treatment framework without converting it into individualized prescribing. fileciteturn33file14

### Restaging

**PASS**

CT, diagnostic laparoscopy, washings, documented PCI ± biopsy and selected PET/CT/EGD are represented at pathway level.

### Response

**PASS**

Stable/improved disease and progression are treated as pathway-dividing states.

### PCI

**PASS**

PCI ≤10 and PCI >10 are represented accurately.

The package explicitly states that PCI is not a standalone treatment rule.

### Extraperitoneal Disease

**PASS**

The package correctly identifies extraperitoneal metastases as incompatible with the favorable peritoneal-only branch.

### Cytoreduction

**PASS**

Complete versus incomplete predicted cytoreduction is explicitly represented.

### HIPEC

**PASS**

HIPEC is presented as selected and downstream.

The package preserves NCCN's limited-evidence/selected-use framing. fileciteturn33file19

### Clinical Trials

**PASS**

Clinical trials are integrated into multiple branches.

### Best Supportive Care

**PASS**

Best supportive care is represented as a legitimate pathway without implying treatment abandonment.

## Layer 3 — Educational QA

### Patient-Facing Readability

**PASS**

Technical terms are introduced and explained.

### Clinical Reasoning

**PASS**

The package includes a longitudinal pathway rather than a disconnected list of facts.

### Misconception Coverage

**PASS**

The package directly corrects:

- peritoneal-dominant ≠ peritoneal-only;
- positive cytology does matter;
- three months ≠ guaranteed surgery;
- PCI ≤10 ≠ automatic HIPEC;
- peritoneal-only ≠ automatic surgery;
- HIPEC ≠ universal standard;
- supportive care ≠ abandonment.

### Uncertainty

**PASS**

HIPEC is labeled selected/evolving.

PIPAC is labeled investigational.

### Patient Safety

**PASS**

No individualized treatment recommendation is provided.

## Layer 4 — Governance QA

### Source-First

**PASS**

PP-specific NCCN materials were searched before production.

### Governance

**PASS**

CORE_WORKING_RULES v1.7 and Gold Specification were reviewed.

CORE rules require PP-specific Source retrieval and prohibit replacing missing project evidence with generic assumptions. fileciteturn32file12

### Gold Discussion Template

**PASS**

The approved Discussion example was used for structure, decision depth, boundary reasoning, patient-facing misconceptions, knowledge graph and evidence-maturity treatment. The governance explicitly requires preservation of Gold Discussion depth and structure. fileciteturn31file2turn31file4

### Immediate Production

**PASS**

Production followed the Approved + Locked Decision Batch without reopening format/depth/ZIP questions.

### Boundary Rule

**PASS**

One final-response Boundary is provided and uses the required four-part structure.

CORE_WORKING_RULES explicitly requires Core / Supporting / Explicitly Excluded / Delegated-to PP and states that Boundary is declared once in the final production response. fileciteturn31file19

## Layer 5 — Adjacent Package Overlap QA

### PP-0223 — Metastatic Gastric Cancer

**Ownership:** overall metastatic gastric cancer.

**PP-0225:** peritoneal-only specialized pathway.

**Result: PASS.**

### PP-0224 — Peritoneal Carcinomatosis

**Ownership:** foundational disease-state characterization.

**PP-0225:** disease-state-specific management pathway.

**Result: PASS.**

### PP-0217 — Response Assessment

**Ownership:** response-assessment methodology/concept.

**PP-0225:** uses response status as a pathway variable.

**Result: PASS.**

### PP-0218 — RECIST-based Assessment

**Ownership:** RECIST methodology.

**PP-0225:** does not reproduce RECIST.

**Result: PASS.**

### PP-0219 — Post-treatment Imaging

**Ownership:** imaging methodology.

**PP-0225:** specifies why/when restaging imaging matters.

**Result: PASS.**

### PP-0226 — HIPEC

**Ownership:** dedicated HIPEC treatment package.

**PP-0225:** pathway interface only.

**Result: PASS.**

### PP-0227 / PP-0228

**Ownership:** detailed palliative/BSC.

**PP-0225:** pathway destination only.

**Result: PASS.**

### PP-0231

**Ownership:** detailed toxicity/supportive care.

**PP-0225:** patient fitness/nutrition interface only.

**Result: PASS.**

### PP-0232

**Ownership:** detailed MDT workflow.

**PP-0225:** explains why MDT review is required.

**Result: PASS.**

## Evidence Traceability Audit

| Evidence Area | Traceability | Result |
|---|---|---|
| Peritoneal-only definition | NCCN v2.2026 | PASS |
| Positive cytology | NCCN v2.2026 | PASS |
| Initial workup | NCCN v2.2026 | PASS |
| Minimum 3-month systemic therapy | NCCN v2.2026 | PASS |
| Restaging | NCCN v2.2026 | PASS |
| PCI | NCCN v2.2026 | PASS |
| Low/high PCI branches | NCCN v2.2026 | PASS |
| Progression branch | NCCN v2.2026 | PASS |
| Extraperitoneal disease branch | NCCN v2.2026 | PASS |
| Cytoreduction feasibility | NCCN v2.2026 | PASS |
| IC/HIPEC selected use | NCCN v2.2025/v2.2026 | PASS |
| HIPEC evidence limitation | NCCN v2.2025 | PASS |
| PIPAC investigational context | NCCN framework | PASS |

## Numerical Evidence Audit

The package preserves only guideline-supported pathway anchors:

- minimum systemic therapy: **3 months**;
- low PCI: **≤10**;
- high PCI: **>10**.

These numbers are presented as pathway context, not as individualized eligibility rules.

**Result: PASS.**

## Clinical Safety Audit

| Safety Item | Result |
|---|---|
| Individual HIPEC eligibility | PASS — not determined |
| Individual PCI calculation | PASS — not performed |
| Individual cytoreduction prediction | PASS — not performed |
| Individual systemic regimen | PASS — not prescribed |
| Individual imaging interpretation | PASS — not provided |
| Individual prognosis | PASS — not provided |
| Surgical recommendation | PASS — not provided |
| RECIST calculation | PASS — delegated |
| Drug dosing | PASS — not provided |
| Treatment switching | PASS — not prescribed |

## Evidence Maturity Audit

### Established

Peritoneal-only pathway, systemic therapy, restaging, PCI, MDT.

**PASS.**

### Selected / evolving

Cytoreduction and IC/HIPEC.

**PASS.**

### Investigational

PIPAC.

**PASS.**

## Knowledge Graph Audit

### Prerequisites

PP-0223, PP-0224, PP-0027, PP-0217, PP-0219.

**PASS.**

### Related

PP-0218, PP-0226, PP-0232 and relevant therapy/surgery packages.

**PASS.**

### Downstream

PP-0226, PP-0227, PP-0228, PP-0231.

**PASS.**

No artificial relationships were introduced merely to fill the graph.

## Gold Depth Integrity Review

The Gold Specification states that future PPs SHALL NOT be compacted or materially reduced relative to approved Gold references and that Gold depth applies to:

- structure;
- CKO;
- KP;
- Evidence Package;
- QA;
- Knowledge Graph;
- evidence traceability;
- patient-facing explanation;
- clinical reasoning and scope documentation. fileciteturn31file5turn31file18

### CKO

**PASS**

Includes:

- metadata;
- atomic question;
- educational objectives;
- scope;
- four-part boundary;
- 40 clinical knowledge blocks;
- patient-facing questions;
- misconceptions;
- clinical pathway;
- safety boundary;
- Knowledge Graph;
- key messages;
- revision history.

### Knowledge Passport

**PASS**

Includes:

- identity;
- classification;
- runtime usage;
- retrieval tags;
- scope;
- patient journey;
- knowledge units;
- evidence maturity;
- evidence hierarchy;
- routing;
- ownership matrix;
- Knowledge Graph;
- governance metadata;
- runtime principle.

### Primary Evidence Package

**PASS**

Includes:

- clinical question;
- scope;
- primary/supporting sources;
- evidence hierarchy;
- evidence matrix;
- detailed evidence notes;
- clinical claims;
- evidence consistency;
- limitations;
- gaps;
- maturity map;
- patient translation;
- boundary verification;
- Knowledge Graph;
- source traceability;
- update triggers.

### QA Report

**PASS**

Includes:

- content QA;
- clinical QA;
- educational QA;
- governance QA;
- adjacent-package overlap;
- evidence traceability;
- numerical audit;
- clinical safety;
- knowledge graph;
- Gold-depth integrity;
- source-first audit;
- locked-decision integrity;
- cross-artifact consistency;
- package integrity.

**Gold-depth result: PASS.**

## Locked Decision Integrity

**PASS**

The production does not reopen the approved scope.

The package does not introduce a competing PP.

No substantive downstream ownership is absorbed.

## Cross-artifact Consistency

| Dimension | Result |
|---|---|
| PP ID | PASS |
| Title | PASS |
| Atomic question | PASS |
| Scope | PASS |
| Boundary | PASS |
| Evidence hierarchy | PASS |
| Clinical pathway | PASS |
| Knowledge Graph | PASS |
| Safety | PASS |
| Final status | PASS |

## Package Integrity

Expected artifacts:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

**All four present.**

No temporary files are included in the ZIP.

## Final QA Decision

| QA Layer | Result |
|---|---|
| Content QA | PASS |
| Clinical QA | PASS |
| Educational QA | PASS |
| Governance QA | PASS |
| Adjacent PP Overlap | PASS |
| Evidence Traceability | PASS |
| Numerical Evidence | PASS |
| Clinical Safety | PASS |
| Evidence Maturity | PASS |
| Knowledge Graph | PASS |
| Gold Depth Integrity | PASS |
| Source-First | PASS |
| Locked Decision Integrity | PASS |
| Cross-artifact Consistency | PASS |
| Package Integrity | PASS |

# PASS — GOLD — READY FOR INTEGRATION

## Revision History

| Version | Date | Summary |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA after Approved + Locked Decision Batch. |
